Direct Oral Anticoagulants for Extended Thromboprophylaxis in Medically Ill Patients: Meta-Analysis and Risk/Benefit Assessment

Journal of Blood Medicine - New Zealand
doi 10.2147/jbm.s149202
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Informa UK Limited

Related search

Active Online Assessment of Patients Using New Oral Anticoagulants: Bleeding Risk, Compliance, and Coagulation Analysis

Seminars in Thrombosis and Hemostasis
Cardiovascular MedicineHematologyCardiology
2012English

Prolonged Anticoagulation in VTE With Direct Oral Anticoagulants: Towards an Individual Analysis of Net Clinical Benefit?

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2016English

Direct Oral Anticoagulants (DOACs)

Vascular Medicine
MedicineCardiovascular MedicineCardiology
2015English

Novel Oral Anticoagulants and Risk

Clinical Oral Implants Research
Oral Surgery
2018English

Direct Oral Anticoagulants: First Airbag

Medical Council
2019English

Efficacy and Safety of Direct Oral Anticoagulants for Risk of Cancer-Associated Venous Thromboembolism

Clinical and Applied Thrombosis/Hemostasis
MedicineHematology
2019English

Thromboprophylaxis With Dalteparin in Medical Patients: Which Patients Benefit?

Vascular Medicine
MedicineCardiovascular MedicineCardiology
2007English

Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis

TH Open
2020English

Direct Oral Anticoagulants in Patients With Thrombophilia: Challenges in Diagnostic Evaluation and Treatment

Advances in Clinical and Experimental Medicine
BiochemistryMedicineGeneticsMolecular Biology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy